4.7 Article

Inframe insertion and splice site variants in MFGE8 associate with protection against coronary atherosclerosis

Journal

COMMUNICATIONS BIOLOGY
Volume 5, Issue 1, Pages -

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s42003-022-03552-0

Keywords

-

Funding

  1. RIKEN Center for Integrative Medical Sciences
  2. Academy of Finland Center of Excellence in Complex Disease Genetics [312062, 336820]
  3. Finnish Foundation for Cardiovascular Research
  4. Sigrid Juselius Foundation
  5. University of Helsinki
  6. Grand Challenge grants
  7. Horizon 2020 Research and Innovation Programme [101016775]
  8. Academy of Finland [331671]
  9. European Union through the European Regional Development Fund [2014-2020.4.01.16-0125]
  10. Estonian Research Council grant [PRG184]
  11. Doctoral Programme in Population Health, University of Helsinki
  12. Business Finland [HUS 4685/31/2016, UH 4386/31/2016]
  13. AbbVie Inc.
  14. AstraZeneca UK Ltd
  15. Biogen MA Inc.
  16. Celgene Corporation
  17. Celgene International II Sarl
  18. Genentech Inc.
  19. Merck Sharp Dohme Corp
  20. Pfizer Inc.
  21. GlaxoSmithKline Intellectual Property Development Ltd.
  22. Sanofi US Services Inc.
  23. Maze Therapeutics Inc.
  24. Janssen Biotech Inc
  25. Novartis AG
  26. Academy of Finland (AKA) [336820, 331671, 331671] Funding Source: Academy of Finland (AKA)

Ask authors/readers for more resources

A genome-wide association study has identified MFGE8 as protective against coronary atherosclerosis in European and East Asian populations. Variants in MFGE8 were found to be associated with a lower risk of coronary atherosclerosis, suggesting the potential for the inhibition of lactadherin production to substantially reduce the risk of coronary heart disease.
A genome-wide association study identifies MFGE8 as protective against coronary atherosclerosis in European and East Asian populations. Cardiovascular diseases are the leading cause of premature death and disability worldwide, with both genetic and environmental determinants. While genome-wide association studies have identified multiple genetic loci associated with cardiovascular diseases, exact genes driving these associations remain mostly uncovered. Due to Finland's population history, many deleterious and high-impact variants are enriched in the Finnish population giving a possibility to find genetic associations for protein-truncating variants that likely tie the association to a gene and that would not be detected elsewhere. In a large Finnish biobank study FinnGen, we identified an association between an inframe insertion rs534125149 in MFGE8 (encoding lactadherin) and protection against coronary atherosclerosis. This variant is highly enriched in Finland, and the protective association was replicated in meta-analysis of BioBank Japan and Estonian biobank. Additionally, we identified a protective association between splice acceptor variant rs201988637 in MFGE8 and coronary atherosclerosis, independent of the rs534125149, with no significant risk-increasing associations. This variant was also associated with lower pulse pressure, pointing towards a function of MFGE8 in arterial aging also in humans in addition to previous evidence in mice. In conclusion, our results suggest that inhibiting the production of lactadherin could lower the risk for coronary heart disease substantially.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available